June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually. The shot ...

Europe's drug watchdog on Friday approved the world's first vaccine for infants and those over 60 against the Respiratory Syncytial Virus, a major cause of hospitalization on the continent, the ...

The European Commission in June approved British drugmaker GSK's vaccine Arexvy to protect older adults. EU approves Pfizer's RSV vaccine to protect infants and older adults Skip to main content ...

Pfizer’s stock has declined 29.4% so far this year against an increase of 8.1% for the industry.. Image Source: Zacks Investment Research In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today that the European ...

The US Food and Drug Administration on Monday approved the first vaccine that protects newborns from respiratory syncytial virus, known as RSV. The vaccine, made by Pfizer, is given to mothers ...

A vaccine to protect infants in their first six months of life — the age group at highest risk of being hospitalized with RSV — is expected to gain FDA approval later this year.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. It had an exceptional launch and generated £1.2 billion in sales in 2023. In the first six months of 2024 ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making ...

The European Commission on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- the first time the bloc has authorised an mRNA shot against a disease other ...

European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually. The approval on Wednesday by the ...